The predicted results were corroborated by findings in patients with T2D which demonstrated over 3-fold higher odds of severe gliclazide-induced hypoglycemia in patients with CYP2C19 NM/RM/UM phenotype treated with omeprazole. The gene discussed is CYP2C19; the disease is type 2 diabetes mellitus.